Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Global Rx-360 Consortium Aims To Curb Pharmaceutical Supply Chain Threats

This article was originally published in PharmAsia News

Executive Summary

Drug manufacturers are forming a consortium called Rx-360 to take the lead in protecting the global pharmaceutical supply chain from threats like the heparin adulterant potentially linked to deaths of 146 U.S. patients last year

You may also be interested in...



U.S. FDA, Industry Aim to Further Strengthen Pharma Supply Chain Quality

While the pharmaceutical industry and U.S. FDA have made progress in better controlling the pharmaceutical supply chain since the heparin crisis a few years ago, they recognize that more needs to be done, said FDA and industry officials at a recent PDA/FDA Pharmaceutical Supply Chain Workshop in Bethesda, Md

U.S. FDA, Industry Aim to Further Strengthen Pharma Supply Chain Quality

While the pharmaceutical industry and U.S. FDA have made progress in better controlling the pharmaceutical supply chain since the heparin crisis a few years ago, they recognize that more needs to be done, said FDA and industry officials at a recent PDA/FDA Pharmaceutical Supply Chain Workshop in Bethesda, Md

In Wake Of Heparin Deaths, FDA Set To Launch Pilot Project Aimed At Preventing Imports Of Adulterated Drugs

BEIJING - One year after adulterated heparin sourced from China began triggering scores of adverse reactions and deaths in U.S. patients, U.S. FDA is preparing to launch a voluntary pilot program aimed at helping prevent contaminated drugs from entering the country

UsernamePublicRestriction

Register

PS140995

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel